Skip to main content
    R

    Rhythm Pharmaceuticals Inc (RYTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $107.48
    -7.54 (-6.56%)

    Market Cap: $7.97B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rhythm Pharmaceuticals Inc (RYTM) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Rhythm Pharmaceuticals (RYTM) trades at 26.4x sales and 84.4x book value. Its P/S of 26.4x is below its 5-year median of 31.0x. Its forward P/E is 333.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E333.3x
    Price to sales26.4x
    Price to book84.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 1554.9% above 5.1x.

    MultipleCurrent5-year median10-year median
    P/S26.4x31.0xN/A
    P/B84.4x20.6x5.1x
    Medians of month-end values through Oct 2026: 57 to 60 months (5-year) and 104 months (10-year).

    Valuation History

    Over the 5 of the 9 year ends shown that have a P/S, its P/S ranged from 26.3x in 2024 to 158.9x in 2021.

    Year endPriceP/SP/B
    2025$107.0436.8x51.5x
    2024$55.9826.3x21.0x
    2023$45.9734.3x16.0x
    2022$29.1264.8x6.2x
    2021$9.98158.9x1.8x
    2020$29.73N/A7.9x
    2019$22.96N/A3.4x
    2018$26.88N/A3.8x
    2017$29.06N/A5.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About RYTM

    What is RYTM's forward P/E ratio?

    Rhythm Pharmaceuticals has a forward P/E ratio of 333.3x.

    What is RYTM's price to sales ratio?

    Rhythm Pharmaceuticals has a price to sales ratio of 26.4x.